Authors
Loading...
This study demonstrates the molecular docking of Kanglixin capsules, revealing 187 targets in non-small cell lung cancer, suggesting therapeutic pathways.
Li et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: